Bio-tech startup Cellivate Technologies raises $1 Mn in seed round

Bio-tech startup Cellivate Technologies has raised $1 million in a seed round led by Antler along with participation from Venture Catalysts, Hatcher+, and We Founder Circle.

The funds will be used to accelerate its R&D efforts, scale up production of its innovative products, and expand its market reach, Cellivate said in a press release.

Launched by Viknish Krishnan Kutty, Cellivate is developing innovative solutions to address critical challenges in cell culture and biomanufacturing. The company's flagship products include advanced microcarriers for scaling up cell growth and a novel cell-based serum designed to replace fetal bovine serum.

According to market research, the cell culture market, especially concerning microcarriers and serum, is expected to reach $33 billion by 2030. 

Cellivate says that its advanced microcarriers and cell-based serum alternatives have the potential to reduce costs, increase efficiency, and address ethical concerns in cell culture processes. Advancements in cell culture and biomanufacturing-related technologies will reduce society’s dependence on animal slaughter since several products/ingredients conventionally derived from animals can be procured from cells.